Diagnosis and treatment of growth hormone deficiency in adults

Nature Reviews Endocrinology

Volumn 9, Issue 6, 2013, Pages 335-345

  Kargi, Atil Y ^a   Merriam, George R ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; PEDIATRICS; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ADULT; DWARFISM, PITUITARY; HUMAN GROWTH HORMONE; HUMANS;

EID: 84879093899     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.77     Document Type: Review

References (136)

1. Raben, M. S. Growth hormone. 1. Physiologic aspects. N. Engl. J. Med. 266, 31-35 (1962).
2. van der Lely, A. J., Tschop, M, Heiman, M. L. & Ghigo, E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25, 426-457 (2004).
3. Lanning, N. J. & Carter-Su, C. Recent advances in growth hormone signaling. Rev. Endocr. Metab. Disord. 7, 225-235 (2006).
4. Le Roith, D., Bondy, C., Yakar, S., Lui, J. L. & Butler, A. The somatomedin hypothesis: 2001. Endocr. Rev. 22, 53-74 (2001).
5. Clemmons, D. R. & Underwood L. E. Nutritional regulation of IGF-I and IGF binding proteins. Annu. Rev. Nutr. 11, 393-412 (1991).
6. Jorgensen, J. O. et al. Metabolic consequences of GH deficiency. J. Endocrinol. Invest. 28 (Suppl. 5), 47-51 (2005).
7. Davidson, M. B. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr. Rev. 8, 115-131 (1987).
8. Moller, N. & Jorgensen, J. O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152-177 (2009).
9. Moller, N. et al. Growth hormone and protein metabolism. Clin. Nutr. 28, 597-603 (2009).
10. Andreassen, T. T. & Oxlund, H. The effects of growth hormone on cortical and cancellous bone. J. Musculoskelet. Neuronal Interact. 2, 49-58 (2001).
11. Ohlsson, C., Bengtsson, B. A., Isaksson, O. G., Andreassen, T. T. & Slootweg, M. C. Growth hormone and bone. Endocr. Rev. 19, 55-79 (1998).
12. Rabinowitz, D. & Zierler, K. L. A metabolic regulating device based on the actions of human growth hormone and of insulin, singly and together, on the human forearm. Nature 199, 913-915 (1963).
13. Parkin, J. M. Incidence of growth hormone deficiency. Arch. Dis. Child. 49, 904-905 (1974).
14. Sassolas, G. et al. GH deficiency in adults: an epidemiological approach. Eur. J. Endocrinol. 141, 595-600 (1999).
15. Stochholm, K. et al. Incidence of GH deficiency-a nationwide study. Eur. J. Endocrinol. 155, 61-71 (2006).
16. Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G. K. & Ghigo, E. Hypopituitarism. Lancet, 369, 1461-1470 (2007).
17. Abs, R. et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin. Endocrinol. (Oxf.) 50, 703-713 (1999).
18. Aimaretti, G. et al. Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). Growth Horm. IGF Res. 14 (Suppl. A), S114-S117 (2004).
19. Aimaretti, G. et al. Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin. Endocrinol. (Oxf.) 61, 320-326 (2004).
20. Schneider, H. J., Kreitschmann-Andermahr, I., Ghigo, E., Stalla, G. K. & Agha, A. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 298, 1429-1438 (2007).
21. Tanriverdi, F., Unluhizarci, K. & Kelestimur, F. Pituitary function in subjects with mild traumatic brain injury: a review of literature and proposal of a screening strategy. Pituitary 13, 146-153 (2010).
22. Agha, A. et al. Anterior pituitary dysfunction in survivors of traumatic brain injury. J. Clin. Endocrinol. Metab. 89, 4929-4936 (2004).
23. Klose, M. et al. Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study. Clin. Endocrinol. (Oxf.) 67, 598-606 (2007).
24. Gleeson, H. K., Gattamaneni, H. R., Smethurst, L., Brennan, B. M. & Shalet, S. M. Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy. J. Clin. Endocrinol. Metab. 89, 662-666 (2004).
25. Mulder, R. L. et al. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat. Rev. 35, 616-632 (2009).
26. Tauber, M., Moulin, P., Pienkowski, C., Jouret, B. & Rochiccioli, P. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J. Clin. Endocrinol. Metab. 82, 352-356 (1997).
27. Toogood, A. A. & Shalet, S. M. Diagnosis of severe growth hormone (GH) deficiency in young adults who received GH replacement therapy during childhood. Acta Paediatr. Suppl. 423, 117-120 (1997).
28. Wacharasindhu, S., Cotterill, A. M., Camacho-Hubner, C., Besser, G. M. & Savage, M. O. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin. Endocrinol. (Oxf.) 45, 553-556 (1996).
29. Molitch, M. E. et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1587-1609 (2011).
30. Cook, D. M. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients-2009 update. Endocr. Pract. 15 (Suppl. 2), 1-29 (2009).
31. Ho, K. K. et al. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur. J. Endocrinol. 157, 695-700 (2007).
32. Longobardi, S. et al. Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J. Clin. Endocrinol. Metab. 81, 1244-1247 (1996).
33. Ho, K. Y. et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J. Clin. Endocrinol. Metab. 64, 51-58 (1987).
34. Frystyk, J., Freda, P. & Clemmons, D. R. The current status of IGF-I assays-a 2009 update. Growth Horm. IGF Res. 20, 8-18 (2009).
35. Hartman, M. L. et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J. Clin. Endocrinol. Metab. 87, 477-485 (2002).
36. Hilding, A. et al. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J. Clin. Endocrinol. Metab. 84, 2013-2019 (1999).
37. Toogood, A. A., Beardwell, C. G. & Shalet, S. M. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin. Endocrinol. (Oxf.) 41, 511-516 (1994).
38. Clemmons, D. R. The diagnosis and treatment of growth hormone deficiency in adults. Curr. Opin. Endocrinol. Diabetes Obes. 17, 377-383 (2010).
39. Kargi, A. Y. & Merriam, G. R. Testing for growth hormone deficiency in adults: doing without growth hormone-releasing hormone. Curr. Opin. Endocrinol. Diabetes Obes. 19, 300-305 (2012).
40. Biller, B. M. et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J. Clin. Endocrinol. Metab. 87, 2067-2079 (2002).
41. Darzy, K. H. et al. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J. Clin. Endocrinol. Metab. 88, 95-102 (2003).
42. Binder, G., Bosk, A., Gass, M., Ranke, M. B. & Heidemann, P. H. Insulin tolerance test causes hypokalaemia and can provoke cardiac arrhythmias. Horm. Res. 62, 84-87 (2004).
43. Shah, A., Stanhope, R. & Matthew, D. Hazards of pharmacological tests of growth hormone secretion in childhood. BMJ 304, 173-174 (1992).
44. Vestergaard, P., Hoeck, H. C., Jakobsen, P. E. & Laurberg, P. Reproducibility of growth hormone and cortisol responses to the insulin tolerance test and the short ACTH test in normal adults. Horm. Metab. Res. 29, 106-110 (1997).
45. Aimaretti, G. et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J. Clin. Endocrinol. Metab. 83, 1615-1618 (1998).
46. Corneli, G. et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur. J. Endocrinol. 153, 257-264 (2005).
47. Yuen, K. C., Biller, B. M., Molitch, M. E. & Cook, D. M. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J. Clin. Endocrinol. Metab. 94, 2702-2707 (2009).
48. Chihara, K. et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur. J. Endocrinol. 157, 19-27 (2007).
49. Petersenn, S., Jung R. & Beil, F. U. Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test. Eur. J. Endocrinol. 146, 667-672 (2002).
50. Popovic, V. et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 356, 1137-1142 (2000).
51. Merriam, G. R. & Hersch, E. C. Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? Clin. Interv. Aging 3, 121-129 (2008).
52. Carroll, P. V. et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83, 382-395 (1998).
53. Cuneo, R. C., Salomon, F., McGauley, G. A. & Sonksen, P. H. The growth hormone deficiency syndrome in adults. Clin. Endocrinol. (Oxf.) 37, 387-397 (1992).
54. Beshyah, S. A. et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin. Endocrinol. (Oxf.) 42, 179-189 (1995).
55. Johannsson, G. et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727-734 (1997).
56. Salomon, F., Cuneo, R. C., Hesp, R. & Sonksen, P. H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321, 1797-1803 (1989).
57. Weaver, J. U. et al. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin. Endocrinol. (Oxf.) 41, 639-648 (1994).
58. Widdowson, W. M. & Gibney, J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 4413-4417 (2008).
59. Woodhouse, L. J., Mukherjee, A., Shalet, S. M. & Ezzat, S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr. Rev. 27, 287-317 (2006).
60. Johannsson, G., Sverrisdottir, Y. B., Ellegard, L., Lundberg, P. A. & Herlitz, H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J. Clin. Endocrinol. Metab. 87, 1743-1749 (2002).
61. Bravenboer, N., Holzmann, P., de Boer, H., Blok, G. J. & Lips, P. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 18, 551-557 (1996).
62. Holmes, S. J., Economou, G., Whitehouse, R. W., Adams, J. E. & Shalet, S. M. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 78, 669-674 (1994).
63. Kaufman, J. M., Taelman, P., Vermeulen, A. & Vandeweghe, M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J. Clin. Endocrinol. Metab. 74, 118-123 (1992).
64. Rosen, T., Hansson, T., Granhed, H., Szucs, J. & Bengtsson, B. A. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. (Copenh.) 129, 201-206 (1993).
65. De Boer, H. et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J. Bone Miner. Res. 9, 1319-1326 (1994).
66. Murray, R. D., Columb, B., Adams, J. E. & Shalet, S. M. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J. Clin. Endocrinol. Metab. 89, 1124-1130 (2004).
67. Rosen, T., Wilhelmsen, L., Landin-Wilhelmsen, K., Lappas, G. & Bengtsson, B. A. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. J. Endocrinol. 137, 240-245 (1997).
68. Wuster, C. et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J. Bone Miner. Res. 16, 398-405 (2001).
69. Johansson, J. O. Fowelin, J., Landin, K., Lager, I. & Bengtsson, B. A. Growth hormone-deficient adults are insulin-resistant. Metabolism 44, 1126-1129 (1995).
70. Cuneo, R. C. Salomon, F., Watts, G. F., Hesp, R. & Sönksen, P. H. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42, 1519-1523 (1993).
71. de Boer, H., Blok, G. J., Voerman, H. J., Phillips, M. & Schouten, J. A. Serum lipid levels in growth hormone-deficient men. Metabolism 43, 199-203 (1994).
72. Abs, R. et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults-a KIMS database analysis. Eur. J. Endocrinol. 155, 79-90 (2006).
73. Maiter, D. et al. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur. J. Endocrinol. 155, 253-260 (2006).
74. Smith, J. C. et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin. Endocrinol. (Oxf.) 56, 493-501 (2002).
75. van der Klaauw, A. A. et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur. J. Endocrinol. 156, 455-462 (2007).
76. Climent, V., Marin F. & Pico, A. Pharmacologic therapy in growth hormone disorders and the heart. Curr. Med. Chem. 14, 1399-1407 (2007).
77. Maison, P. & Chanson, P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648-2652 (2003).
78. Merola, B. et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J. Clin. Endocrinol. Metab. 77, 1658-1661 (1993).
79. Colao, A. et al. Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clin. Endocrinol. (Oxf.) 61, 360-366 (2004).
80. Leonsson, M. et al. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin. Endocrinol. (Oxf.) 57, 751-759 (2002).
81. Murata, M. et al. A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults and children. Eur. J. Endocrinol. 148, 333-338 (2003).
82. Holmes, S. J. & Shalet, S. M. Factors influencing the desire for long-term growth hormone replacement in adults. Clin. Endocrinol. (Oxf.) 43, 151-157 (1995).
83. Koltowska-Haggstrom, M., Mattsson, A. F. & Shalet, S. M. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur. J. Endocrinol. 161 (Suppl. 1), S51-S64 (2009).
84. Attanasio, A. F. et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J. Clin. Endocrinol. Metab. 82, 82-88 (1997).
85. Bates, A. S., Van't Hoff, W., Jones, P. J. & Clayton, R. N. The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 81, 1169-1172 (1996).
86. Rosen, T. & Bengtsson, B. A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285-288 (1990).
87. Sherlock, M. et al. Mortality in patients with pituitary disease. Endocr. Rev. 31, 301-342 (2010).
88. Tomlinson, J. W. et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425-431 (2001).
89. Stochholm, K., Christiansen, J., Laursen, T. & Gravholt, C. H. Mortality and reduced growth hormone secretion. Horm. Res. 68 (Suppl. 5), 173-176 (2007).
90. Stochholm, K. et al. Mortality and GH deficiency: a nationwide study. Eur. J. Endocrinol. 157, 9-18 (2007).
91. Aguiar-Olieveira, M. H. et al. Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J. Clin. Endocrinol. Metab. 95, 714-721 (2010).
92. Attanasio, A. F. et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. J. Clin. Endocrinol. Metab. 87, 1600-1606 (2002).
93. Gibney, J. et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84, 2596-2602 (1999).
94. Hoffman, A. R. et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 2048-2056 (2004).
95. Beauregard, C. et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 2063-2071 (2008).
96. Al-Shoumer, K. A. et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults. Eur. J. Endocrinol. 135, 559-567 (1996).
97. Gotherstrom, G. et al. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J. Clin. Endocrinol. Metab. 94, 809-816 (2009).
98. Burman, P. et al. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J. Clin. Endocrinol. Metab. 82, 550-555 (1997).
99. Ezzat, S. et al. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J. Clin. Endocrinol. Metab. 87, 2725-2733 (2002).
100. Nguyen, V. T. & Misra, M. Transitioning of children with GH deficiency to adult dosing: changes in body composition. Pituitary 12, 125-135 (2009).
101. Claessen, C. M. et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J. Clin. Endocrinol. Metab. 98, 352-361 (2013).
102. Svensson, J., Sunnerhagen, K. S. & Johannsson, G. Five years of growth hormone replacement therapy in adults: age-and gender-related changes in isometric and isokinetic muscle strength. J. Clin. Endocrinol. Metab. 88, 2061-2069 (2003).
103. Maison, P. et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J. Clin. Endocrinol. Metab. 89, 2192-2199 (2004).
104. Gotherstrom, G., Bengtsson, B. A., Bosaeus, I., Johannsson, G. & Svensson, J. 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J. Clin. Endocrinol. Metab. 92, 1442-1445 (2007).
105. Monson, J. P., Jönsson, P., Koltowska-Häggström, M. & Kourides, I. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin. Endocrinol. (Oxf.) 67, 623-628 (2007).
106. Colao, A. et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 3416-3424 (2008).
107. Pfeifer, M. et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 84, 453-457 (1999).
108. Sesmilo, G. et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. 133, 111-122 (2000).
109. Sesmilo, G. et al. Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. J. Clin. Endocrinol. Metab. 86, 1518-1524 (2001).
110. Oliveira, J. L. et al. Congenital growth hormone (GH) deficiency and atherosclerosis: effects of GH replacement in GH-naive adults. J. Clin. Endocrinol. Metab. 92, 4664-4670 (2007).
111. Baum, H. B. et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann. Intern. Med. 125, 883-890 (1996).
112. Johannsson, G., Rosén, T., Bosaeus, I., Sjöström, L. & Bengtsson, B. A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 81, 2865-2873 (1996).
113. Drake, W. M. et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin. Endocrinol. (Oxf.) 54, 525-532 (2001).
114. Gotherstrom, G., Bengtsson, B. A., Bosaeus, I., Johannsson, G. & Svensson, J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur. J. Endocrinol. 156, 55-64 (2007).
115. Baum, H. B. et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 83, 3184-3189 (1998).
116. Moock, J. et al. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania. Eur. J. Endocrinol. 160, 17-24 (2009).
117. Urushihara, H., Fukuhara, S., Tai, S., Morita, S. & Chihara, K. Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult-and childhood-onset Japanese hypopituitary adults with GH deficiency during GH replacement. Eur. J. Endocrinol. 156, 637-645 (2007).
118. Sathiavageeswaran, M. et al. Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month study. Eur. J. Endocrinol. 156, 439-447 (2007).
119. Murray, R. D. et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin. Endocrinol. (Oxf.) 51, 565-573 (1999).
120. Gilchrist, F. J., Murray, R. D. & Shalet, S. M. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin. Endocrinol. (Oxf.) 57, 363-370 (2002).
121. Rosilio, M. et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J. Clin. Endocrinol. Metab. 89, 1684-1693 (2004).
122. McKenna, S. et al. The QoL-AGHDA: An instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual. Life Res. 8, 373-383 (1999).
123. Takala, J. et al. Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785-792 (1999).
124. Moe, K. E. et al. Growth hormone in postmenopausal women after long-term oral estrogen replacement therapy. J. Gerontol. A. Biol. Sci. Med. Sci. 53, B117-B124 (1998).
125. Bidlingmaier, M. et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J. Clin. Endocrinol. Metab. 91, 2926-2930 (2006).
126. Giavoli, C. et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 89, 5397-5401 (2004).
127. Losa, M. et al. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid 18, 1249-1254 (2008).
128. Holmes, S. J. & Shalet, S. M. Which adults develop side-effects of growth hormone replacement? Clin. Endocrinol. (Oxf.) 43, 143-149 (1995).
129. Clayton, P. E., Banerjee, I., Murray, P. G. & Renehan, A. G. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat. Rev. Endocrinol. 7, 11-24 (2011).
130. Sklar, C. A. et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 87, 3136-3141 (2002).
131. Child, C. J. et al. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur. J. Endocrinol. 165, 217-223 (2011).
132. Arnold, J. R., Arnold, D. F., Marland, A., Karavitaki, N. & Wass, J. A. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin. Endocrinol. (Oxf.) 70, 435-438 (2009).
133. Karavitaki, N. et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin. Endocrinol. (Oxf.) 64, 556-560 (2006).
134. Olsson, D. S. et al. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur. J. Endocrinol. 161, 663-669 (2009).
135. Carel, J. C. et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J. Clin. Endocrinol. Metab. 97, 416-425 (2012).
136. Savendahl, L. et al. Long-term mortality and causes of death in isolated, GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J. Clin. Endocrinol. Metab. 97, E213-E217 (2012).